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Abstract 
Acetaminophen (APAP) administration results in hepatotoxicity and hematotoxicity in cats. The response to three 
different treatments against APAP poisoning was evaluated. Free glutathione (GSH) (200mg/kg), niosomal GSH (14 
mg/kg) and free amino acids (180 mg/kg of N-acetylcysteine and 280 mg/kg of methionine) were administered to 
cats  that  were  intoxicated  with  APAP  (a  single  dose  of  150  mg/kg,  p.o.).  Serum  concentration  of  alanine 
aminotransferase  (ALT)  along  with  serum,  liver  and  erythrocyte  concentration  of  GSH  and  methemoglobin 
percentage were measured before and 4, 24 and 72 hours after APAP administration. Free GSH (200 mg/kg) and 
niosomal GSH (14 mg/kg) were effective in reducing hepatotoxicity and hematotoxicity in cats intoxicated with a 
dose of 150 mg/kg APAP. We conclude that both types of treatments can protect the liver and haemoglobin against 
oxidative  stress  in  APAP  intoxicated  cats.  Furthermore,  our  results  showed  that  treatment  with  niosomal  GSH 
represents an effective therapeutic approach for APAP poisoning. 
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Introduction 
Acetaminophen  (APAP)  is  one  of  the  most  widely 
used  analgesic  and  antipyretic  in  human  medical 
practice  (Mirochnitchenko  et  al.,  1999).  However, 
APAP  is  highly  toxic  to  cats  and  dogs  when 
administered at human doses. The common factor in 
APAP  poisoning  is  the  erroneous  administration  by 
the  owner  without  prior  consultation  with  the 
veterinarian.  For  this  reason,  APAP  intoxication 
represents  a  common  cause  of  feline  and  canine 
toxicoses  reported  to  veterinary  poison  treatment 
centers (Jones et al., 1992; Allen, 2003).  
In particular, there is no safe dose of APAP for cats.  
Studies have shown that a dose of 50 to 100 mg/kg 
bodyweight of APAP is toxic to cats (Sellon, 2001).  
There is also evidence which indicates that a dose as 
low  as  10  mg/kg  bodyweight  can  produce  signs  of 
toxicity  and  lead  to  death  (Aronson  and  Drobatz, 
1996).  The  pathways  for  APAP  metabolism  are  via 
glucuronidation  and  sulfation,  followed  by  renal 
excretion of the conjugates in most of the mammalian 
species (Davis el al., 1974; Savides et al., 1984).  
A  small  percentage  of  APAP  is  oxidized  by 
cytochrome  P450  enzymes  (metabolic  activation  of 
APAP) to the highly reactive metabolite, N-acetyl-p-
benzoquinoneimine  (NAPQI)  (Davis  et  al.,  1974). 
NAPQI binds to glutathione (GSH) and is excreted in 
the form of mercapturic acid conjugate (Davis et al., 
1974).  
The domestic cat (Felis catus) is extremely sensitive 
to the toxic effects of APAP for several reasons. One 
of the main reasons is slow and poor glucuronidation 
ability in this species.  Poor glucuronidation is due to 
UDP glucuronosyltransferase 1A6 (UGT1A6), the key 
isoenzyme responsible for APAP detoxification, being 
not expressed in the liver of cats.  
In the Felidae family, lack of UGT1A6 isoenzyme is 
the  result  of  multiple  inactivating  mutations  of  the 
gene  that  encodes  UGT1A6,  rendering  the  species 
defective  for  APAP  metabolism  (Court  and 
Greenblatt,  2000;  Shrestha  et  al.,  2011).  Another 
reason for APAP toxicity is the limited capacity of the 
sulfation pathway in cats compared to other species 
(Savides et al., 1984). For both the reasons mentioned 
above,  APAP  persists  in  the  blood  and  as  a  result, 
APAP is metabolized by cytochrome P-450 enzymes 
to the highly reactive metabolite NAPQI which further 
depletes the GSH reserves (Allen, 2003).  
Another detrimental effect of NAPQI is that it reacts 
with  cellular  proteins  and  affects  mitochondrial 
respiration  (early  mitochondrial  injury).  NAPQI-
induced  oxidative  stress  also  leads  to  a  delayed 
mitochondrial injury (Jaeschke et al., 2011) and cell 
death.  Erythrocytes  are  the  cells  that  are  most 
susceptible to the toxic effects of NAPQI in the cats 
(McConkey et al., 2009).  
Two key components in erythrocytes are susceptible 
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and  the  sulfhydryl  groups  of  the  globulin  chains. 
NAPQI causes the oxidation of ferrous iron (Fe2+) to 
ferric  iron  (Fe3+),  which  converts  hemoglobin  to 
methemoglobin (Richardson, 2000). In this regard, it 
is important to note that cats have a relative deficiency 
of  methemoglobin  reductase  in  erythrocytes.  Thus, 
methemoglobinemia  is  a  primary  and  prominent 
feature of APAP toxicity in this species.  
Another  deleterious  effect  of  NAPQI  in  cats  is  the 
oxidation  of  thiol  groups  of  hemoglobin  with  the 
consequent  production  of  large  amounts  of 
methemoglobin and Heinz bodies (Desnoyers, 2000). 
This particular reaction in cats has been attributed to 
the  high  numbers  of  sulfhydryl  groups  that  are 
exposed on the surface of feline haemoglobin.  
Traditional  treatment  of  APAP  toxicity  involves  the 
administration of alternate sulfhydryl donors in order 
to  inhibit  the  formation  of  the  reactive  metabolite 
(Savides et al., 1985). N-acetylcysteine (NAC) is the 
most  widely  used  compound  for  the  treatment  of 
APAP  toxicity  (Polson  and  Lee,  2005).  This 
compound  protects  against  oxidative  injury  by 
providing cysteine groups for GSH biosynthesis and 
also by directly inactivating NAPQI via its sulfhydryl 
group (Corcoran and Wong, 1986).  
In contrast to NAC, GSH has not been used clinically 
in APAP poisoning because it is rapidly hydrolyzed 
and has a short plasma half-life ranging from 2 to 15 
minutes  (Wendel  and  Jaeschke,  1982;  Hong  et  al., 
2005;  Saito  et  al.,  2010).  However,  recent  studies 
indicate that intravenous administration of GSH was 
effective  in  treating  mice  exhibiting  APAP  toxicity, 
because it causes an increase in the levels of hepatic 
GSH  due  to  de  novo  synthesis  from  amino  acids 
released  by  the  hydrolysis  of  GSH  (Knight  et  al., 
2002; Saito et al., 2010; Masubuchi et al., 2011). 
Niosomal GSH could be effective in the treatment of 
APAP  intoxication.  Encapsulation  into  vesicles 
protects  the  tripeptide  from  being  hydrolysed  and 
thereby  permits  a  higher  concentration  to  reach  the 
liver.  Niosomes  (non–ionic  surfactant  vesicles)  are 
nanovesicular drug delivery systems formed by self-
assembly  of  molecules  of  nonionic  surfactant  and 
cholesterol. The surfactants used and also the prepared 
niosomes are biodegradable, biocompatible and non-
immunogenic (Sankhyan and Pawar, 2012).  
These  vesicles  are  used  in  the  transport  of  active 
compounds  in  the  form  of  drugs,  genes  or  vaccine 
fractions.  Niosomes can modify the pharmacokinetics 
and bioavailability of the drugs (Baillie et al., 1985; 
Uchegbu  and  Florence,  1995).  After  intravenous 
administration,  the  biological  behavior 
(pharmacokinetics,  arrival  at  the  site  of  action, 
therapeutic  efficacy  and  adverse  reactions)  of  the 
niosomes  is  controlled  by  a  complex  set  of 
physicochemical  and  biological  factors  that  include 
the size of the vesicles, shape and composition of the 
membrane,  biochemical,  anatomical  and 
immunological barriers (Moghimi et al., 2012).  
Thus,  not  only  the  characteristics,  but  also  the 
performance  of  the  prepared  niosomes  can  be 
exquisitely  controlled  by  altering  the  composition, 
concentration  of  various  additives,  size,  lamellarity 
and  surface  charge  of  vesicles  (Khan  et  al.,  2011). 
Studies show that the therapeutic efficacy of the drugs 
can  be  significantly  improved  by  reducing  the 
clearance  rate,  targeting  to  the  specific  site  and  by 
protecting  the  encapsulated  drug  (Sankhyan  and 
Pawar, 2012).  
The purpose of this study was to compare the efficacy 
of NAC, free GSH and niosomal GSH in the treatment 
of APAP toxicity in cats.  
Material and Methods 
Drugs and reagents 
Reduced  L-GSH,  O-phthaldialdehyde  (OPA),  DL-
dithiothreitol  (DTT),  tris  hydroxymethyl 
aminomethane  and  sodium  tetraborato,  dihexadecyl 
phosphate (DCP) were obtained from Sigma Aldrich 
(St Louis, USA). Sodium acetate was obtained from 
Farmitalia,  Carlo  Erba  (Milano,  Italy).  Sodium 
dihydrogen  phosphate  monohydrate,  cholesterol  and 
chlorhydric  acid  were  obtained  from  JT  Baker 
(Xalostos, Mexico).  
Methanol and acetonitrile HPLC grade were obtained 
from JT Baker (Phillipsburg, USA). Metaphosphoric 
acid  (MPA)  was  obtained  from  Riedel-de  Haën 
(Seelze,  German);  ethylenediaminetetraacetic  acid 
solution  0.342  mol/l  (EDTA)  was  obtained  from 
Wiener Lab, Argentina. APAP (®Paracetamol Raffo, 
1  g);  ALT  UV  AA  diagnostic  kit  (Wiener  Lab, 
Argentina);  hemoglobin  standart  (Wiener  Lab, 
Argentina);  potassium  ferricyanide  (Biopack, 
Argentina); potassium cyanide (Biopack, Argentina). 
Sorbitol  monostearate  (Span  60)  was  obtained  from 
Fluka, Spain; polycarbonate membranes (Isopore) of 
0.8,  0.4  and  0.2  µm  were  obtained  from  Millipore. 
Saline  Sodium  Chloride  0.9%  was  obtained  from 
Roux-Ocefa U (Argentina).  
Preparation of GSH niosomes 
Preparation of niosomes was carried out at ~65°C. It 
was essential to prepare the vesicles at a temperature 
above the gel-liquid transition temperature of span 60. 
Niosomes  were  prepared  by  hydration  of  melted 
surfactant/cholesterol/DCP (67.5: 27.5: 5) at 65°C in a 
50  ml  beaker  (Niemiec  et  al.,  1995;  Uchegbu  and 
Vyas, 1998; Confalonieri et al., 2010). The non-ionic 
surfactant was melted using a magnetic stirrer with a 
heated plate (AREC, Velp Scientifica), once melted, 
cholesterol and DCP were added and the mixture was 
hydrated  with  a  GSH  solution  in  saline  sodium 
chloride (5.4 M) by shaking with the magnetic stirrer 
for 60 min. Then the suspensions were processed for 3 http://www.openveterinaryjournal.com 
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min  at  16,000  rpm  (Ultraturrax  T-25)  and  finally, 
sonicated for 3 minutes at 40 Khz power (Mod Testlab 
Ultrasound TBO10). Once this process was completed 
the  suspensions  were  maintained  at  65°C  and 
manually  extruded,  five  times  each,  successively 
through  polycarbonate  membranes  (0.8,  0.4  and  0.2 
μm). 
Determination of GSH entrapment efficiency 
The removal of the unbound GSH from the vesicles 
was accomplished by ultracentrifugation at 150,000 g 
at 4°C for 90 minutes (Ultracentrifuge Sorvall Ultra 
Pro 80). The isolated pellets were washed twice, each 
with saline sodium chloride, and recentrifuged again 
for  1  hour.  The  supernatant  was  removed  and  the 
pellets were resuspended in the saline sodium chloride 
to obtain a total lipid concentration of 20 mM.  
The amount of entrapped GSH was determined after 
disruption  of  vesicles  by  lipid  extraction  method 
(Bligh and Dyer, 1959). The GSH incorporated into 
the  niosomes  was  analysed  by  HPLC  as  described 
previously  (Denzoin  et  al.,  2008).  Entrapment 
efficiency (E%) was expressed as a percentage of the 
total amount of GSH found in the disrupted vesicles. 
The  entrapment  efficiency  of  GSH  is  calculated  as 
follows (Ruckmani et al., 2000):  
 
         
 m                     
       m           
       
 
Characterization of GSH niosomes 
Vesicles  were  characterised  by  optical  and  light 
polarized  microscopy  (Olympus  BX40)  for  vesicle 
formation, agglutination and morphology. Samples of 
the niosomal  formulations  were examined under the 
optical  microscope  and  were  photographed  at  a 
magnification of 1000×. The size distribution and the 
polydispersivity index of the vesicles was determined 
using  dynamic  light  scattering  at  25°C  with  a 
scattering angle of 90° (Zetasizer Nano ZS, Malvern).  
Animals 
Sixteen healthy adult, domestic shorthaired cats were 
used for this study. The mean age of the cats was 3.2 
years  old  (range  2-5  years),  and  the  average  body 
weight was 3.84 ± 0.69 kg.  
The cats were fed with cat food for adult maintenance 
(Association of American Feed Control Officials) on 
an ad libitum basis from 8:00 am to 6:00 pm daily. 
Water was also provided ad libitum. The animals were 
kept  fasting  for  12  hours  prior  to  starting  the 
experimental  protocol.  This  study  was  performed 
according to the standards established by the Animal 
Welfare  Commission  of  Faculty  of  Veterinary 
Science. 
Experimental protocol 
The animals were divided in four groups containing 
four  animals  each  (Groups  I,  II,  III  and  IV)  and 
anesthetized  using  a  combination  of  ketamine  (15 
mg/kg)  and  xylazine  (0.5  mg/kg).  An  intravenous 
catheter  (Abbocath  G18)  was  placed  in  the  jugular 
vein to facilitate administration of drugs used for the 
treatment and an intravenous catheter (Abbocath G22) 
was placed in antebrachial cephalic vein for sampling 
the blood.  
After recovery from the anaesthesia, the animals were 
transferred  back  to  their  cages.  Group  I  (control) 
received  a  single  dose  of  150  mg/kg  of  APAP 
administrated orally. This dose was established by us 
in a previous work (Castro, 2001). Group II received a 
single oral dose of 150 mg/kg of APAP and a dose of 
GSH  200  mg/kg  (mouse  dose  according  to  Wendel 
and  Jaeschke  (1982))  solubilized  in  100  ml  of 
physiological saline solution by intravenous infusion.  
Group III received a single oral dose of 150 mg/kg 
APAP  and  a  dose  of  niosomal  GSH  14  mg/kg 
solubilized in 100 ml of physiological saline solution 
by intravenous infusion. This was the maximum dose 
of GSH that could be encapsulated into the niosomes. 
Group IV received a single oral dose of 150 mg/kg of 
APAP  and  an  oral  dose  of  180  mg/kg  of  N-
acetylcysteine and 280 mg/kg of methionine dissolved 
in 10  ml of physiological saline  solution of  sodium 
chloride 0.9% using a probe K30 tube. 
Blood and liver sampling 
Blood and liver samples were collected from all the 
animals at 0, 4, 24 and 72 hours after dosing. Blood 
samples (5 ml) were collected and immediately placed 
into  refrigerated  tubes  containing  EDTA  as  an 
anticoagulant.  
Three  liver  biopsies  of  each  animal  were  collected 
using  Menghini's  technique  (Menghini,  1958)  using 
local  anaesthesia.  The  liver  biopsies  were  placed  in 
chilled physiological saline solution. The percentage 
of  methemoglobin  was  determined  by  colorimetry 
(Sato, 2005).  
Levels  of  Alanine  animotransferase  (ALT)  was 
measured  at  37°C  in  spectrophotometer  (Pharmacia 
Ultrospec  III)  using  the  optimized  method  UV 
(Wiener  Lab).  GSH  concentrations  in  plasma, 
erythrocytes and liver were determined according to 
the  method  previously  described  (Denzoin  et  al., 
2008).  Liver  protein  concentration  was  determined 
using the Lowry et al. (1951) method.  
Statistical analysis  
A completely randomized design was established with 
measurements  repeated  over  time,  using  a  linear 
mixed  model  with  an  autoregressive  correlation 
structure of order 1 (InfoStat 2011p version). 
Results 
GSH niosomes 
The GSH entrapment efficiency of niosomes was 49.9 
%. Photomicrographs of the GSH niosomes are shown 
in Fig. 1.  http://www.openveterinaryjournal.com 
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The  GSH  niosomes  were  spherical  in  shape.  No 
aggregates  were  observed.  The  mean  particle 
diameters were 422 nm. 
 
 
Fig. 1. Photomicrograph of GSH loaded niosomes composed 
of  Spam  60/cholesterol/DCP  (67.5:  27.5:  5).  The  arrows 
show the vesicles.  
 
Clinical signs 
Group  I  and  Group  IV  exhibited  clinical 
manifestations of APAP acute intoxication.  Clinical 
characteristics  included  cyanosis  and  tachypnea 
between  2  and  6  hours  post  treatment  followed  by 
anorexia  and  depression  between  24  and  72  hours. 
Groups  II  and  III  showed  only  anorexia.  No  deaths 
were recorded during the entire experimental protocol.  
Group IV showed no significant differences in ALT 
activity (p>0.05) compared to Group I. On the other 
hand,  Group  II  and  Group  III  showed  a  small  but 
significant  (p<0.05)  increase  in  ALT  levels  when 
compared to Groups I and IV (Fig. 2). 
Fig. 2. ALT levels in the treated groups. Group I: 150 mg/kg 
of  APAP.  Group  II  150  mg/kg  of  APAPand  GSH  200 
mg/kg. Group III 150 mg/kg of APAPand niosomal  GSH 
(14 mg/kg). Group IV 150 mg/kg of APAP, 180 mg/kg of 
N-acetylcysteine and 280 mg/kg of methionine. The square 
indicates  the  basal  values.  Different  letters  indicate 
significant differences between the groups (p<0.05). 
No  significant  differences  in  methemoglobin  levels 
were observed between Groups I and IV. Groups II 
and III showed significant differences with respect to 
Groups  I  and  IV  (Fig.  3).  Although  no  significant 
differences  were  observed  between  groups  treated 
with free GSH and niosomal GSH, the group treated 
with  free  GSH  (group  II)  showed  lower 
methemoglobin formation than the group treated with 
niosomal GSH (group III). 
 
Fig. 3. Methemoglobin percent in the treated groups. Group 
I: 150 mg/kg of APAP. Group II 150 mg/kg of APAPand 
GSH  200  mg/kg.  Group  III  150  mg/kg  of  APAPand 
niosomal GSH (14 mg/kg). Group IV 150 mg/kg of APAP, 
180  mg/kg  of  N-acetylcysteine  and  280  mg/kg  of 
methionine  .The  square  indicates  basal  values.  Different 
letters  indicate  significant  differences  between  the  groups   
(p<0.05). 
 
There  was  a  significant  increase  in  plasma 
concentration  of  GSH  at  4  hours  post  treatment  in 
groups II and III when compared to the control group 
(group I). Likewise, significant differences in plasma 
GSH  concentrations  were  found  between  groups  II 
and III (Fig. 4). 
Liver  GSH  concentration  decreased  at  4  hours  post 
treatment  in  groups  I,  II  and  IV,  while  group  III 
(treated with niosomal GSH) showed an increase of 
GSH liver concentration at this time. In Groups II and 
III liver GSH concentration remained elevated above 
the baseline at 24 and 72 hours (Fig. 5). 
Group  I  showed  a  significant  decrease  in  GSH 
concentration  in  the  erythrocyte,  which  remained 
below  the  basal  levels  at  72  hours  (Fig.  6)  when 
compared to groups II, III and IV. 
Discussion 
Clinical  symptoms  of  APAP  intoxication  in  cats 
include  rapid  and  significant  methemoglobin 
formation (Nash et al., 1984). Furthermore, oxidation 
of  hemoglobin  leads  to  the  denaturation  of 
hemoglobin whose precipitation results in Heinz body 
formation and hemolytic anemia (Nash et al., 1984; 
McConkey  et  al.,  2009).  Methemoglobin  and http://www.openveterinaryjournal.com 
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hemolytic  anemia  result  in  respiratory  distress, 
depression, and weakness that can lead to the death of 
the  animal  even  prior  to  the  development  of  liver 
toxicity.  
GSH treatment at 200 mg/kg by intravenous infusion 
and  treatment  with  niosomal  GSH  at  14mg/kg  by 
intravenous  infusion  were  found  to  be  effective  in 
decreasing the levels of methemoglobin formation and 
hepatotoxic effects of APAP poisoning (Fig. 2 and 3). 
 
 
 
Fig. 4. Plasmatic GSH concentrations in the treated groups. 
Group  I:  150  mg/kg  of  APAP.  Group  II  150  mg/kg  of 
APAPand  GSH  200  mg/kg.  Group  III  150  mg/kg  of 
APAPand niosomal GSH (14 mg/kg). Group IV 150 mg/kg 
of APAP, 180 mg/kg of N-acetylcysteine and 280 mg/kg of 
methionine  .The  square  indicates  basal  values.  Different 
letters  indicate  significant  differences  between  groups 
(p<0.05). 
 
 
Fig.  5.  Liver  GSH  concentrations  in  the  treated  groups. 
Group  I:  150  mg/kg  of  APAP.  Group  II  150  mg/kg  of 
APAPand  GSH  200  mg/kg.  Group  III  150  mg/kg  of 
APAPand niosomal GSH (14 mg/kg). Group IV 150 mg/kg 
of APAP, 180 mg/kg of N-acetylcysteine and 280 mg/kg of 
methionine  .The  square  indicates  basal  values.  Different 
letters  indicate  significant  differences  between  the  groups 
(p<0.05). 
 
 
 
Fig.  6.  GSH  concentration  in  erythrocytes  in  the  treated 
groups. Group I: 150 mg/kg of APAP. Group II 150 mg/kg 
of  APAP  and  GSH  200  mg/kg.  Group  III  150  mg/kg  of 
APAPand niosomal GSH (14 mg/kg). Group IV 150 mg/kg 
of APAP, 180 mg/kg of N-acetylcysteine and 280 mg/kg of 
methionine  .The  square  indicates  basal  values.  Different 
letters indicate significant differences between the groups (p 
<0.05). 
 
Treatment with a single oral dose of N-acetyl cysteine 
and  methionine  was  not effective and did  not  show 
any  significant  differences  when  compared  to  the 
control group (Fig. 2 and 3). This treatment therefore 
would not be effective against APAP intoxication at a 
dose  of  150  mg/kg.  Groups  II  and  III  showed  a 
decreased formation of methemoglobin. Both groups 
showed significant differences from group I and group 
IV (Fig. 3).  
The  percentage  of  methemoglobin  was  lower  in  the 
group that was treated with free GSH (group II). The 
formation of methemoglobin during intoxication with 
APAP is a distinctive feature of this poisoning in both 
dogs and cats (MacNaughton, 2003). Methemoglobin 
formation occurs by the reaction of NAPQI with the 
thiol-reactive  groups  of  the  hemoglobin  molecule 
(Nash  et  al.,  1984;  Savides  et  al.,  1984).  The  high 
GSH concentration found in the liver of both species 
could  inactivate  NAPQI  formed  in  this  organ  after 
APAP  administration  and  thus  would  reduce  the 
formation  of  methemoglobin.  Additionally,  elevated 
GSH  plasma  concentrations  found  at  4  hours  post 
treatment in groups II and III could inactivate NAPQI 
in  plasma,  and  contribute  to  reduce  methemoglobin 
formation. Although NAPQI has been proposed as the 
molecule  responsible  for  the  formation  of 
methemoglobin  by  most  authors,  McConkey  et  al. 
(2009) underestimate the importance of NAPQI in the 
formation  of  methemoglobin.  They  propose  that  the 
metabolite  para-aminophenol,  which  is  co-oxidized 
with the hemoglobin molecule, is more important than 
NAPQI. However, it is important to note that both the http://www.openveterinaryjournal.com 
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metabolites  (NAPQI  and  para-aminophenol)  are 
inactivated by GSH (McConkey et al., 2009).  
The hepato-protective effect of GSH in groups II and 
III would be related to an increase in the GSH hepatic 
concentration  in  both  groups  after  treatment.  The 
GSH-induced  mechanism  of  hepatoprotection 
involves improving the capacity of the hepatocytes to 
inactivate NAPQI, avoiding the covalent modification 
of  cellular  proteins  and  blocking  the  initiation  of 
APAP toxicity (Corcoran and Wong, 1986). Free GSH 
administered intravenously is rapidly degraded by the 
  g  s   h    c    i    h     zym   γ-glutamyl 
    s    i  s   (γGT).  The  amino  acids  released  by 
GSH  hydrolysis  are  absorbed  by  hepatocytes  and 
subsequently  utilized  for  de  novo  GSH  synthesis 
(Saito  et  al.,  2010).  APAP  poisoning  leads  to 
decreased hepatic concentrations of GSH.  
Accordingly,  treatment  with  GSH  would  be  an 
effective solution because it provides the amino acids 
that  contribute  to  restoration  of  liver  GSH 
concentrations (Saito et al., 2010; Masubuchi et al., 
2011), and inactivate the NAPQI formed during the 
metabolic phase of APAP intoxication.  
In addition to the hepatoprotective effect of GSH in 
the  metabolic  phase  of  APAP  intoxication,  there 
would also be an effect of the treatment during the 
post metabolic phase. The covalent binding of NAPQI 
to  mitochondrial  proteins  is  a  critical  point  that 
connected  the  metabolic  phase  of  APAP  toxicity  to 
mitochondrial  dysfunction  and  initiates  the  post 
metabolic  phase  of  intoxication  (Jaeschke  et  al., 
2011).  
This mitochondrial dysfunction leads to inhibition of 
mitochondrial  respiration  with  the  consequent 
formation of reactive oxygen species and formation of 
peroxynitrite  in  the  mitochondrial  matrix  –an  effect 
that  consumes  mitochondrial  GSH  (Jaeschke  et  al., 
2011).  
The elevated GSH liver concentrations observed in the 
group treated with free GSH (group II) would help to 
accelerate the restoration of mitochondrial GSH levels 
and inactivate the reactive species formed at this stage, 
thereby limiting hepatocellular necrosis. These effects 
are associated with a smaller increase in ALT levels in 
group II when compared to group I. 
Hepatoprotective effects were observed in the group 
treated  with  niosomal  GSH  (group  III).  While  the 
results  between  groups  II  and  III  showed  no 
significant differences, ALT activities were lower in 
the  group  treated  with  niosomes  (group  III)  when 
compared to the group treated with free GSH (group 
II).  
The group treated with niosomal GSH had a marked 
increase  in  hepatic  GSH  concentration  which  was 
significantly different from all other treatments. This 
finding could be related to the selective accumulation 
of niosomal GSH in the liver (Uchegbu and Florence, 
1995; Hashim et al., 2010).  
The  niosomal  vesicles  have  a  preferential  passive 
targeting in the liver (Azmin et al., 1985; Baillie et al., 
1985; Uchegbu and Florence, 1995). After intravenous 
administration, the vesicles of a size greater than 200 
nm  are  rapidly  removed  from  circulation  because, 
after  opsonisation,  niosomes  are  recognized  and 
phagocytosed by Kupffer cells of the liver (Ishida et 
al., 2002; Mozafari, 2006). Vesicles of 400 nm can 
also  access  the  hepatocytes  depending  on  the  lipid 
composition  and  their  membrane  electric  charge 
(Romero et al., 1999). 
Group IV (treated with a combination of amino acids 
methionine 180mg/kg and N- acetylcysteine 280 mg / 
kg) showed no significant differences respect to the 
group I (control). Several authors suggest the use of 
N-acetylcysteine  (NAC)  for  the  treatment  of  APAP 
intoxication in cats (Gaunt et al., 1981; Savides et al., 
1985)  and  NAC  is  also  used  for  the  treatment  of 
poisoning  in  humans  (Shen  et  al.,  2011). Thus,  our 
results do not concur with previously published data. 
One major reason for the observed discrepancy may 
be related to the differences in the dosing schedule. 
Gaunt et al. (1981) used an oral dosing regimen at 200 
mg/kg  of  NAC  every  two  hours  in  cats  that  were 
intoxicated  with  145  mg/kg  of  APAP  and  observed 
significant  differences  in  the  formation  of 
methemoglobin  respect  to  the  control  and  found  no 
increase in plasmatic ALT activity.  
Savides et al. (1985), using oral and intravenous doses 
of NAC in animals treated with 120 mg/kg of APAP, 
found  both  routes  of  the  treatment  to  be  effective, 
reporting  a  decrease  in  the  formation  of 
methemoglobin  and  increased  erythrocyte  GSH 
concentration. In a more recent report, Avizeh et al. 
(2010) treated a group of cats with a single dose of 
NAC  (100  mg/kg)  along  with  the  administration  of 
150 mg/kg of APAP and their results agree with those 
obtained by Gaunt et al. (1981). 
In conclusion, our results have shown that both free 
GSH  (200  mg/kg)  and  niosomal  GSH  (14  mg/kg) 
treatments  were  highly  effective  in  reducing  both 
hepatotoxicity  and  hematotoxicity  in  cats  that  were 
intoxicated  with  a  dose  of  150  mg/kg  APAP. 
Niosomes  are  a  novel  drug  delivery  system  which 
offers  advantages  over  other  conventional  vesicular 
delivery systems.   
Our results show that treatment with niosomal GSH 
represents an effective therapeutic approach for APAP 
poisoning. Our results were obtained despite using a 
lower dose of GSH. This clearly demonstrates that the 
encapsulated  drug  is  selectively  transported  to  the 
liver.  
Our findings can be of immense help in the treatment 
of  pathophysiological  conditions  that  result  in http://www.openveterinaryjournal.com 
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oxidative stress in the liver. From our work emerges 
the  potential  for  the  development  of  a  combined 
therapy  that  employs  both  niosomal  and  free  GSH. 
Our results suggest that this therapy is more promising 
than those currently used for the treatment of APAP-
induced toxicity. 
___________________________________________ 
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